These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 25438190)

  • 1. Novel therapeutic approaches to autosomal dominant polycystic kidney disease.
    LaRiviere WB; Irazabal MV; Torres VE
    Transl Res; 2015 Apr; 165(4):488-98. PubMed ID: 25438190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease.
    Stayner C; Brooke DG; Bates M; Eccles MR
    Curr Med Chem; 2019; 26(17):3081-3102. PubMed ID: 29737248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Trials and a View Toward the Future of ADPKD.
    Kim H; Hwang YH
    Adv Exp Med Biol; 2016; 933():105-121. PubMed ID: 27730438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease.
    Chebib FT; Torres VE
    Clin J Am Soc Nephrol; 2018 Nov; 13(11):1765-1776. PubMed ID: 30049849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Somatostatin analogues and mTOR inhibitors].
    Perico N; Cortinovis M; Remuzzi G
    G Ital Nefrol; 2016; 33(5):. PubMed ID: 27796020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New therapies for ADPKD].
    Rathaus M
    G Ital Nefrol; 2007; 24(6):526-34. PubMed ID: 18278756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials.
    Myint TM; Rangan GK; Webster AC
    Nephrology (Carlton); 2014 Apr; 19(4):217-26. PubMed ID: 24460701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Modern treatment of autosomal dominant polycystic kidney disease].
    Wołyniec W; Jankowska MM; Rutkowski B
    Pol Merkur Lekarski; 2008 Oct; 25(148):374-9. PubMed ID: 19145940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in management of autosomal-dominant polycystic kidney disease.
    Potts JW; Mousa SA
    Am J Health Syst Pharm; 2017 Dec; 74(23):1959-1968. PubMed ID: 29167138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy.
    Wüthrich RP; Serra AL; Kistler AD
    Kidney Blood Press Res; 2009; 32(5):380-7. PubMed ID: 19887826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Trends in ADPKD Research.
    Shin YB; Park JH
    Adv Exp Med Biol; 2016; 933():3-11. PubMed ID: 27730430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?].
    Cornec-Le Gall E; Le Meur Y
    Nephrol Ther; 2014 Nov; 10(6):433-40. PubMed ID: 25086476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease.
    Santoro D; Pellicanò V; Visconti L; Trifirò G; Buemi M; Cernaro V
    Expert Opin Investig Drugs; 2015; 24(9):1199-218. PubMed ID: 26125126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defective glycolysis and the use of 2-deoxy-D-glucose in polycystic kidney disease: from animal models to humans.
    Magistroni R; Boletta A
    J Nephrol; 2017 Aug; 30(4):511-519. PubMed ID: 28390001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Development in Autosomal Dominant Polycystic Kidney Disease: Opportunities and Challenges.
    Chebib FT; Perrone RD
    Adv Kidney Dis Health; 2023 May; 30(3):261-284. PubMed ID: 37088528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autosomal Dominant Polycystic Kidney Disease: Is There a Role for Autophagy?
    Ponticelli C; Moroni G; Reggiani F
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spectrum of autosomal dominant polycystic kidney disease in children and adolescents.
    Reddy BV; Chapman AB
    Pediatr Nephrol; 2017 Jan; 32(1):31-42. PubMed ID: 27034070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin in renal physiology and autosomal dominant polycystic kidney disease.
    Messchendorp AL; Casteleijn NF; Meijer E; Gansevoort RT
    Nephrol Dial Transplant; 2020 Aug; 35(8):1306-1316. PubMed ID: 31077332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inhibitors of intra-cystic secretion: novel therapies in ADPKD (Autosomal Dominant Polycystic Kidney Disease)].
    Miranda N; Miranda F; Rinaldi L; Stratigis S; Capasso G
    G Ital Nefrol; 2013; 30(1):. PubMed ID: 23832438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.